# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming ph...
https://twitter.com/DrTedros/status/1778423967105139108
HC Wainwright & Co. analyst Vernon Bernardino maintains Aethlon Medical (NASDAQ:AEMD) with a Buy and lowers the price ta...
Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Fi...
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1...